Diabetic Kidney Disease Pathophysiology and Therapeutic Approaches

Diabetic kidney disease (DKD) arises from persistent hyperglycaemia and associated metabolic derangements that trigger haemodynamic alterations, endothelial dysfunction and oxidative stress within the kidney. Glomerular hyperfiltration and increased intraglomerular pressure drive podocyte injury, mesangial expansion and basement membrane thickening. Progressive loss of glomerular integrity promotes proteinuria and chronic inflammation, with activation of profibrotic pathways such as transforming growth factor-β signalling leading to extracellular matrix deposition and tubulointerstitial fibrosis. Therapeutic strategies traditionally focus on tight glycaemic control, blood pressure lowering and blockade of the renin-angiotensin system. Recent advances include agents that modulate the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate axis to restore endothelial function, inhibitors of phosphodiesterase-5 to improve microcirculation, and novel small molecules that target oxidative pathways. In parallel, therapies enhancing autophagy and growth factors such as FGF21, as well as interventions to stabilise microvascular pericytes via BMP7 modulation, are under investigation. SGLT2 inhibitors and incretin-based drugs have also demonstrated renoprotective effects beyond glucose lowering by attenuating inflammation and fibrosis. This evolving landscape underscores a multi-targeted approach aimed at halting progression to end-stage renal disease and reducing global healthcare burden.

Research from Nature Portfolio

Recent studies have illuminated autophagy-dependent mechanisms in renal tubular cells, demonstrating that prostaglandin E1 analogues can reverse insulin resistance through induction of an FGF21-mediated autophagic response, thereby preserving tubular integrity. Parallel work using phosphodiesterase-5 inhibitors has revealed a novel miR-22/BMP7 axis that maintains capillary density, reduces perivascular inflammation and stabilises endothelial function, slowing disease progression in rodent models. Furthermore, activation of soluble guanylate cyclase with cinaciguat in diabetic rats has been shown to restore glomerular cGMP levels, attenuate TGF-β and ERK1/2 signalling, and prevent podocyte apoptosis and fibrosis, highlighting central molecular pathways amenable to pharmacological modulation.

Diabetic Kidney Disease Pathophysiology and Therapeutic Approaches publication trend

The graph below shows the total number of articles in diabetic kidney disease pathophysiology and therapeutic approaches across all publications each year (not limited to Nature Index journals).

Technical terms

Glomerular filtration rate: The rate at which blood is filtered through the glomeruli, indicating renal function.

Proteinuria: The presence of excess proteins in urine, a hallmark of glomerular injury.

Autophagy: A cellular degradation process that removes damaged organelles and maintains cellular homeostasis.

Cyclic guanosine monophosphate (cGMP): A second messenger mediating vasodilation and anti-fibrotic signals in renal tissue.

Podocyte: A specialised epithelial cell in the glomerulus essential for filtration barrier integrity.

Fibrosis: The excessive accumulation of extracellular matrix proteins leading to tissue scarring and loss of function.

References

1. Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution. Cell Reports Medicine (2023).
2. The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats. International Journal of Molecular Sciences (2023).
3. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective. International Journal of Molecular Sciences (2018).
4. Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy. Scientific Reports (2018).
5. Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. Scientific Reports (2017).
6. Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats. Scientific Reports (2017).